BOCA RATON, Fla., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF), a vertically integrated, multi-state cannabis operator, announces that in order to assist the Company in managing near-term working capital requirements, the Company and Jim Cacioppo, the Company’s Chairman and Chief Executive Officer, have agreed to certain amendments to Mr. Cacioppo’s employment agreement (collectively, the “Employment Agreement Amendments”). All of the Employment ...

All right, welcome back to Worldwide Exchange. As we close on the 6 a. m.hour, a check of a few big stories that we're following this morning. The US says it collected more than $200 billion in tariffs this [music] year, according to new data from Customs and Border Protection. The figure comes as a [music] Supreme Court weighs the legality of those duties.President Trump's filing a $10 billion defamation lawsuit against the BBC. The president [music] is accusing the British broadcaster of producing a false ...

2 TORONTO--(BUSINESS WIRE)--Organigram Global Inc (NASDAQ: OGI) (TSX: OGI), (the "Company†or "Organigram†), Canada's #1 recreational cannabis company by market share, is pleased to announce record results for the fourth quarter and twelve months ended September 30, 2025 ("Q4 Fiscal 2025†or "Fiscal 2025"). All financial information in this press release is expressed in Canadian dollars ("$"). FOURTH QUARTER 2025 FINANCIAL HIGHLIGHTS FISCAL 2025 FINANCIAL HIGHLIGHTS FISCAL 2025 COMPANY HIGHLIGHTS 2 "Fiscal ...

Core Viewpoint - President Trump is considering reclassifying marijuana from a Schedule I to a Schedule III drug, which could significantly impact the cannabis industry and research opportunities [1][6][10]. Industry Impact - Reclassifying marijuana as a Schedule III drug would ease the buying and selling of cannabis, potentially increasing profitability for the cannabis industry [6][7]. - The reclassification would lower barriers to research, allowing for more extensive studies on marijuana [2][6]. - Cannabis stocks surged following reports of Trump's consideration to ease federal restrictions on marijuana [9][12]. Legislative Context - The Biden administration had previously pursued reclassification but did not implement changes before Trump left office [15]. - Various bills have been introduced in Congress to lower marijuana's classification or decriminalize it, but none have been signed into law [15]. Public Sentiment and Political Commentary - Senator Ron Wyden criticized Trump for misleading the public regarding the legality of marijuana, emphasizing that reclassification does not equate to decriminalization [10][11].

Core Viewpoint - Canopy Growth Corporation is making strategic moves to strengthen its position in the cannabis industry, particularly through the acquisition of MTL Cannabis Corp, while facing current stock price challenges [1][2][3]. Company Overview - Canopy Growth Corporation, listed on Nasdaq as CGC, is a significant player in the cannabis sector, involved in the production and sale of cannabis products for both medical and recreational markets [1]. - The company's current stock price is $1.66, reflecting a decrease of approximately 4.89% [3]. Recent Developments - Alliance Global Partners has adjusted its rating for Canopy Growth to Neutral and raised the price target from C$2 to C$2.50 following the announcement of the acquisition of MTL Cannabis Corp [2]. - The acquisition involves obtaining all issued and outstanding common shares of MTL Cannabis and settling associated debts, positioning Canopy Growth as a leading medical cannabis business in Canada [2]. Market Performance - Canopy Growth's stock has experienced significant volatility over the past year, with a high of $3.14 and a low of $0.77, and currently has a market capitalization of approximately $396.8 million [4]. - Today's trading volume for CGC is notably high, with 101,136,052 shares exchanged on the NASDAQ exchange [4].

The legal status of marijuana in the U.S. remains scattered and confusing.A sharp pull-back in marijuana stocks dinged the value of Tilray Brands (TLRY 10.04%) shares on Monday. At the end of last week, investor hopes rose that President Donald Trump would take an important step toward the de facto legalization of the drug, but those hopes didn't materialize on Monday. Investors eagerly sold out of Tilray, leaving the stock with a 10% loss that trading session. Awaiting a signaturePot stock bulls came out i ...

President Donald Trump told reporters on Monday he is weighing an executive order to reclassify marijuana as a Schedule III substance. The potential action could transform the cannabis market, reduce legal punishments and allow for easier scientific research.TLRY stock is moving. See the chart and price action here. “We are looking at that very strongly,” Trump said in response to reports that he is looking at directing agencies to treat marijuana as a Schedule III drug.Read Next: Elon Musk Prepares SpaceX ...

Cannabis Industry & Tilray Brands - Tilray Brands anticipates potential rescheduling of marijuana to schedule three drug by President Trump, which would reduce federal restrictions [1][3] - Rescheduling would allow Tilray to enter the US market, leveraging research and clinical studies from Canada and Europe, focusing on medical cannabis [5] - Tilray aims to collaborate with the FDA, hospitals, and doctor groups to provide cannabis for medical purposes, such as cancer, epilepsy, stress, and sleep [5][6] - Tilray has over 6 million square feet of cannabis grow space in Canada and Europe, planning to bring strains and genetics to the US [6] - Tilray estimates a potential US medical cannabis market of $10 billion, with a target of 3% to 10% market share, translating to a $300 million to $1 billion business [8] - Tilray has a $50 million business selling cannabis drinks in Canada, and sees potential opportunities in the US with regulated hemp THC products [14] Market Trends & Economic Data - S&P 500 equal weighted index has been outperforming recently, up about 3% in the last month [22] - Healthcare sector (XLV) is the best performing sector this quarter, up 12%, while financials are up about 2% [24] - Crude oil settled at the lowest point in four years at $5665 per barrel, down about 20% this year, while energy sector is up about 5% year-to-date [29][30] - Bitcoin is down 22% year-to-date, with shorts in control and a washout point at $75,000 [33] Women in the Workplace - A McKenzie report indicates a gap between men and women in seeking promotions in corporate environments [36] - A study indicates 86% of senior women leaders are more ambitious than five years ago, seeking flexibility, autonomy, and control [37] - 89% of women queried said they've made a massive change in the last few years, with 71% of those women making that decision by choice [40]

Joining us now for the Start Movers podcast, Lisa matera. All right. I have to start with Massachusetts based I robot. I. T. , the Roomba, came out in 2002. So it's been a while. But what happened is that earnings at the firm that they sold more than 40 million of these things, ¥40 million, more than 40 million. But the earnings declined because right after COVID, you had supply chain issues and then you had the cheaper alternatives coming out. I know people are techs. I mean, like $49.99%, I'd say, Oh, yea ...

Key Takeaways Weed stocks dropped Monday afternoon, reversing early gains on hopes President Trump could soon issue an executive order reclassifying marijuana. An expected reclassification from a Schedule I to a Schedule III drug would help companies in the sector reduce their taxes and relax banking restrictions. Weed stocks aren't flying so high anymore. Shares of Tilray Brands (TLRY) dropped nearly 5%, Canopy Growth (CGC) slipped 3%, and other cannabis stocks also lost ground in recent trading, reve ...